Delaware – September 2020.iQure Pharma Inc. (iQure), a company dedicated to preclinical and early clinical development of new therapeutics, received its first data from a subchronic toxicology study with iQ‑007.
We are pleased to announce that the first assessment of an in vivo subchronic toxicology data looks positive. Seven days of dosing with iQ‑007 at 80 mg/kg, 250 mg/kg and 500 mg/kg per day, were studied in mice after intragastric injection. The aim of the study was to assess blood morphology along with the status of vital organs including liver, kidney and spleen. Initial reading of the data indicates that there are no statistically significant changes in blood or obvious alteration of organs after subchronic administration of iQ-007 at the three dose levels.
Dr Joe Wettstein, Chief Scientific Officer
Although this data is encouraging, we are treating the study with caution as we await the final report. Results show that iQ‑007 appears safe when given once daily over a seven-day period. This is especially important for patients who need long-term treatment, which is common in treating neuropathic pain. Moreover, as the data indicate a good safety profile across all doses, there is potential for a wide therapeutic index given its efficacy at 90 mg/kg p.o. as seen in pain-related experiments. Combining efficacy in pain and epilepsy models with the safety profile emerging from this study provides solid ground for iQ‑007 as a prospective new medicine to treat neuropathic pain and epilepsy.
Comments